Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05068713
Other study ID # LIVER-PAM
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 24, 2021
Est. completion date January 5, 2024

Study information

Verified date January 2024
Source University of Sao Paulo General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

LIVER PAM A randomized, controled, open and unicentric trial comparing high (MAP 85-90 mmHg) and low (65-70 mmHg) target of mean arterial pressure in the first 24 hours after liver transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 174
Est. completion date January 5, 2024
Est. primary completion date January 5, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Older than 18 y - Admitted in the ICU for a post operative care after liver transplant Exclusion Criteria: - Consent refusal - Liver transplant due to acute liver failure - Renal transplant ( Previous or concomitant) - Refusal from the healthcare provider responsible for the patient - Renal substitution therapy in the prior 15 days - Pregnancy - Re-Transplant (Liver transplant in the previous 6 month) - Hepatorenal syndrome current treatment (Use of terlipressin + Albumin) - Refractory and persistent shock during or after transplant

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Usual Care + High Target of Mean Arterial Pressure
Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
Usual Care
Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.

Locations

Country Name City State
Brazil Hospital Das Clínicas Da Faculdade de Medicina Da Universidade de São Paulo São Paulo SAO Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of Acute Kidney Disfunction Incidence of acute kidney Disfunction according to kdigo criteria. 7 days
Secondary Mortality percentage of mortality in 28 days 28 days
Secondary re-transplant percentage of re-transplant in 28 days 28 days
Secondary Lenght of Hospitay Stay LOS in 28 days 28 days
Secondary Lenght of ICU Stay ICU LOS in 28 days 28 days
Secondary Days alive and out of hospital in 28 days Number of days alive and out of hospital in 28 days 28 days
Secondary Substitutive Renal Therapy percentage of TSR in 7 days 7 days
Secondary Days Alive and free of renal disfunction Days Alive and free of renal disfunction in 28 days 28 days
Secondary Acute kidney insufficiency according to Urinary NGAL on d0 and D2 Percentage of renal disfunction according to NGAL criteria on D0 and D2 0d and 2d
Secondary MAKE28 Major Kidney Events ( Death, persistent acute kidney disfunction or need of RRT in 28 days) 28 days
Secondary Liver graft primary disfunction ( Initial Poor Function) percentage of Initial Poor Function in 7 days 7 days
Secondary Liver graft primary disfunction (primary nonfunction) percentage of primary nonfunction in 10 days 10 days
Secondary Surgical site infection percentage of SSI in 28 days 28 days
Secondary Need of Transfusion percentage of Transfusion requirement in 7 days 7 days
Secondary Postoperative Major bleeding in 7 days Bleeding that requires 2 units of blood transfusion in a single day or the need of a reoperation due to bleeding in the first 24 hours after surgery. 7 days
Secondary Incidence of Arrythmia requiring clinical treatment percentage of Arrhythmia requiring treatment in 7 days 7 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05818644 - Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Recruiting NCT04443322 - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT03165916 - Study to Compare the Incidence of Biliary Complications After Liver Transplantation N/A
Withdrawn NCT04216303 - Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
Recruiting NCT04506398 - Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
Not yet recruiting NCT05853484 - Home-based Bimodal Lifestyle Intervention in Patients With Liver Cirrhosis Awaiting Orthotopic Liver Transplantation N/A
Not yet recruiting NCT05036031 - Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
Recruiting NCT05065125 - Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlass™) for Post-liver Transplant Anastomotic Stricture
Recruiting NCT06060392 - Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus N/A
Enrolling by invitation NCT05195944 - Semaglutide vs Sitagliptin Phase 4
Completed NCT05255510 - Risk of Acute Kidney Injury in Living Liver Donor Surgery
Not yet recruiting NCT06048445 - Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Completed NCT04182256 - Magnetic Spiderman for Preparation of Liver Donation N/A
Recruiting NCT04327427 - Outcome Analysis of Aspirin in Liver Transplantation
Recruiting NCT04477967 - Design and Implementation of the Pediatric Liver Transplantation Biobank
Recruiting NCT05109156 - Preoperative Sepsis Timeline, Profile and Its Association With Recipient Outcome Following Live Donor Liver Transplant
Recruiting NCT06124209 - Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial Phase 4